Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma

Fumihiko Hirai, Takashi Seto, Takeharu Yamanaka, Ryo Toyozawa, Eiko Inamasu, Miyako Kojo, Gouji Toyokawa, Yosuke Morodomi, Yoshimasa Shiraishi, Tomoyoshi Takenaka, Masafumi Yamaguchi, Mitsuhiro Takenoyama, Yukito Ichinose

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: Thymic carcinoma is a rare mediastinal neoplasm, and the prognosis of patients with advanced thymic carcinoma is poor. No standard chemotherapeutic regimen has yet been established for the disease. This is the first report to evaluate the role of amrubicin, a novel anthracycline anticancer drug, in second-line and beyond treatment for patients with platinumrefractory advanced thymic carcinoma. Methods: This study was a review of thymic carcinoma patients who had received amrubicin monotherapy between June 2003 and December 2011 for the progression of disease previously treated with platinum-based chemotherapy. Amrubicin was administered at 35 or 40 mg/m2 for three consecutive days every 3 weeks, until progression. Results: Nine patients with recurrent thymic carcinoma were registered. Their median age was 61 years (range 45-72), and the patients included five males and four females. All nine patients had Masaoka's Stage IVb disease. There were three squamous cell carcinomas, one adenocarcinoma, one small-cell carcinoma and two other histological types. The mean number of chemotherapy cycles was five (range 2-13). Grade 3 or higher toxicities included mainly neutropenia (55.5%), anemia (25.0%) and febrile neutropenia (11.1%). No treatment-related deaths were observed. The response rate was 44.4% (95% confidence interval: 19-73). The median progression- free survival after the amrubicin monotherapy was 4.9 months, while the median overall survival was 6.4 months. Conclusions: Single-agent amrubicin was found to be potentially useful as second-line and beyond chemotherapy for patients with advanced thymic carcinoma. Further multi-institutional prospective studies are warranted.

Original languageEnglish
Article numberhyt106
Pages (from-to)1018-1022
Number of pages5
JournalJapanese journal of clinical oncology
Volume43
Issue number10
DOIs
Publication statusPublished - Oct 1 2013

Fingerprint

Thymoma
Platinum
Drug Therapy
Therapeutics
Mediastinal Neoplasms
Febrile Neutropenia
Small Cell Carcinoma
Anthracyclines
amrubicin
Neutropenia
Disease-Free Survival
Disease Progression
Anemia
Squamous Cell Carcinoma
Adenocarcinoma
Prospective Studies
Confidence Intervals
Survival
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Hirai, F., Seto, T., Yamanaka, T., Toyozawa, R., Inamasu, E., Kojo, M., ... Ichinose, Y. (2013). Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma. Japanese journal of clinical oncology, 43(10), 1018-1022. [hyt106]. https://doi.org/10.1093/jjco/hyt106

Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma. / Hirai, Fumihiko; Seto, Takashi; Yamanaka, Takeharu; Toyozawa, Ryo; Inamasu, Eiko; Kojo, Miyako; Toyokawa, Gouji; Morodomi, Yosuke; Shiraishi, Yoshimasa; Takenaka, Tomoyoshi; Yamaguchi, Masafumi; Takenoyama, Mitsuhiro; Ichinose, Yukito.

In: Japanese journal of clinical oncology, Vol. 43, No. 10, hyt106, 01.10.2013, p. 1018-1022.

Research output: Contribution to journalArticle

Hirai, F, Seto, T, Yamanaka, T, Toyozawa, R, Inamasu, E, Kojo, M, Toyokawa, G, Morodomi, Y, Shiraishi, Y, Takenaka, T, Yamaguchi, M, Takenoyama, M & Ichinose, Y 2013, 'Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma', Japanese journal of clinical oncology, vol. 43, no. 10, hyt106, pp. 1018-1022. https://doi.org/10.1093/jjco/hyt106
Hirai, Fumihiko ; Seto, Takashi ; Yamanaka, Takeharu ; Toyozawa, Ryo ; Inamasu, Eiko ; Kojo, Miyako ; Toyokawa, Gouji ; Morodomi, Yosuke ; Shiraishi, Yoshimasa ; Takenaka, Tomoyoshi ; Yamaguchi, Masafumi ; Takenoyama, Mitsuhiro ; Ichinose, Yukito. / Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma. In: Japanese journal of clinical oncology. 2013 ; Vol. 43, No. 10. pp. 1018-1022.
@article{a8c3044e1cc0429392661d731b4af9ee,
title = "Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma",
abstract = "Objective: Thymic carcinoma is a rare mediastinal neoplasm, and the prognosis of patients with advanced thymic carcinoma is poor. No standard chemotherapeutic regimen has yet been established for the disease. This is the first report to evaluate the role of amrubicin, a novel anthracycline anticancer drug, in second-line and beyond treatment for patients with platinumrefractory advanced thymic carcinoma. Methods: This study was a review of thymic carcinoma patients who had received amrubicin monotherapy between June 2003 and December 2011 for the progression of disease previously treated with platinum-based chemotherapy. Amrubicin was administered at 35 or 40 mg/m2 for three consecutive days every 3 weeks, until progression. Results: Nine patients with recurrent thymic carcinoma were registered. Their median age was 61 years (range 45-72), and the patients included five males and four females. All nine patients had Masaoka's Stage IVb disease. There were three squamous cell carcinomas, one adenocarcinoma, one small-cell carcinoma and two other histological types. The mean number of chemotherapy cycles was five (range 2-13). Grade 3 or higher toxicities included mainly neutropenia (55.5{\%}), anemia (25.0{\%}) and febrile neutropenia (11.1{\%}). No treatment-related deaths were observed. The response rate was 44.4{\%} (95{\%} confidence interval: 19-73). The median progression- free survival after the amrubicin monotherapy was 4.9 months, while the median overall survival was 6.4 months. Conclusions: Single-agent amrubicin was found to be potentially useful as second-line and beyond chemotherapy for patients with advanced thymic carcinoma. Further multi-institutional prospective studies are warranted.",
author = "Fumihiko Hirai and Takashi Seto and Takeharu Yamanaka and Ryo Toyozawa and Eiko Inamasu and Miyako Kojo and Gouji Toyokawa and Yosuke Morodomi and Yoshimasa Shiraishi and Tomoyoshi Takenaka and Masafumi Yamaguchi and Mitsuhiro Takenoyama and Yukito Ichinose",
year = "2013",
month = "10",
day = "1",
doi = "10.1093/jjco/hyt106",
language = "English",
volume = "43",
pages = "1018--1022",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Amrubicin as second-line and beyond treatment for platinum-refractory advanced thymic carcinoma

AU - Hirai, Fumihiko

AU - Seto, Takashi

AU - Yamanaka, Takeharu

AU - Toyozawa, Ryo

AU - Inamasu, Eiko

AU - Kojo, Miyako

AU - Toyokawa, Gouji

AU - Morodomi, Yosuke

AU - Shiraishi, Yoshimasa

AU - Takenaka, Tomoyoshi

AU - Yamaguchi, Masafumi

AU - Takenoyama, Mitsuhiro

AU - Ichinose, Yukito

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Objective: Thymic carcinoma is a rare mediastinal neoplasm, and the prognosis of patients with advanced thymic carcinoma is poor. No standard chemotherapeutic regimen has yet been established for the disease. This is the first report to evaluate the role of amrubicin, a novel anthracycline anticancer drug, in second-line and beyond treatment for patients with platinumrefractory advanced thymic carcinoma. Methods: This study was a review of thymic carcinoma patients who had received amrubicin monotherapy between June 2003 and December 2011 for the progression of disease previously treated with platinum-based chemotherapy. Amrubicin was administered at 35 or 40 mg/m2 for three consecutive days every 3 weeks, until progression. Results: Nine patients with recurrent thymic carcinoma were registered. Their median age was 61 years (range 45-72), and the patients included five males and four females. All nine patients had Masaoka's Stage IVb disease. There were three squamous cell carcinomas, one adenocarcinoma, one small-cell carcinoma and two other histological types. The mean number of chemotherapy cycles was five (range 2-13). Grade 3 or higher toxicities included mainly neutropenia (55.5%), anemia (25.0%) and febrile neutropenia (11.1%). No treatment-related deaths were observed. The response rate was 44.4% (95% confidence interval: 19-73). The median progression- free survival after the amrubicin monotherapy was 4.9 months, while the median overall survival was 6.4 months. Conclusions: Single-agent amrubicin was found to be potentially useful as second-line and beyond chemotherapy for patients with advanced thymic carcinoma. Further multi-institutional prospective studies are warranted.

AB - Objective: Thymic carcinoma is a rare mediastinal neoplasm, and the prognosis of patients with advanced thymic carcinoma is poor. No standard chemotherapeutic regimen has yet been established for the disease. This is the first report to evaluate the role of amrubicin, a novel anthracycline anticancer drug, in second-line and beyond treatment for patients with platinumrefractory advanced thymic carcinoma. Methods: This study was a review of thymic carcinoma patients who had received amrubicin monotherapy between June 2003 and December 2011 for the progression of disease previously treated with platinum-based chemotherapy. Amrubicin was administered at 35 or 40 mg/m2 for three consecutive days every 3 weeks, until progression. Results: Nine patients with recurrent thymic carcinoma were registered. Their median age was 61 years (range 45-72), and the patients included five males and four females. All nine patients had Masaoka's Stage IVb disease. There were three squamous cell carcinomas, one adenocarcinoma, one small-cell carcinoma and two other histological types. The mean number of chemotherapy cycles was five (range 2-13). Grade 3 or higher toxicities included mainly neutropenia (55.5%), anemia (25.0%) and febrile neutropenia (11.1%). No treatment-related deaths were observed. The response rate was 44.4% (95% confidence interval: 19-73). The median progression- free survival after the amrubicin monotherapy was 4.9 months, while the median overall survival was 6.4 months. Conclusions: Single-agent amrubicin was found to be potentially useful as second-line and beyond chemotherapy for patients with advanced thymic carcinoma. Further multi-institutional prospective studies are warranted.

UR - http://www.scopus.com/inward/record.url?scp=84885112513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885112513&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyt106

DO - 10.1093/jjco/hyt106

M3 - Article

C2 - 23917962

AN - SCOPUS:84885112513

VL - 43

SP - 1018

EP - 1022

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 10

M1 - hyt106

ER -